Genetic imbalance related to cisplatin-based chemoresistance in epithelial ovarian cancer.
OBJECTIVE
To identify genetic imbalance related to chemoresistance in epithelial ovarian cancer.


METHODS
We screened abnormal chromosomal regions in cisplatin-resistant and cisplatin-sensitive human ovarian cancer cell lines employing comparative genomic hybridization (CGH). We also documented non-random chromosome gains and losses with cisplatin-resistant and cisplatin-sensitive primary epithelial ovarian tumors from patients.


RESULTS
There were extensive chromosome changes in cisplatin-resistant and cisplatin-sensitive cell lines. Gains of 1q12-22, 17q21-22 and loss of 3p21-24 were significantly more common in drug-resistant tumors from patients compared to the drug-sensitive group.


CONCLUSIONS
The special chromosomal aberrances might provide us with a clue for further investigation of the dominant mechanism that leads to a drug-resistant phenotype.
Huanchun
Y
Y
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang PR of China. yinghuanchun73k@yahoo.com.cn
Shulan
Z
Z
Jing
L
L
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002869:Chromosome Aberrations; D002945:Cisplatin / Q000627:therapeutic use*; D055028:Comparative Genomic Hybridization; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics*
D000970:Antineoplastic Agents; D002945:Cisplatin